PD-1 Inhibitor for Disseminated Mycobacterium avium Infection in a Person With HIV

Area of Science:

• Immunology
• Infectious Diseases
• Oncology

Background:

• Disseminated Mycobacterium avium infection (DM) is a severe opportunistic infection in individuals with human immunodeficiency virus (HIV).
• Standard treatment combining antiretroviral therapy (ART) and antimycobacterial agents can be ineffective in certain cases, leading to persistent infections.

Purpose of the Study:

• To investigate the efficacy of programmed cell death protein 1 (PD-1) inhibitor therapy in a patient with HIV and refractory disseminated Mycobacterium avium infection.
• To evaluate the impact of PD-1 inhibition on T-cell exhaustion and M avium-specific immune responses.

Main Methods:

• Case report of a patient with HIV and disseminated Mycobacterium avium infection.
• Treatment failure with standard antiretroviral and anti-M avium drugs.
• Administration of PD-1 inhibitor therapy.
• Assessment of T-cell exhaustion markers and M avium-specific T-cell responses before and after PD-1 inhibitor treatment.

Main Results:

• The patient's disseminated Mycobacterium avium infection was refractory to standard antiretroviral and anti-M avium therapies.
• Following PD-1 inhibitor treatment, a reversal of T-cell exhaustion was observed.
• An enhanced Mycobacterium avium-specific T-cell response was detected.
• Complete clearance of Mycobacterium avium was achieved after PD-1 inhibitor therapy.

Conclusions:

• Programmed cell death protein 1 (PD-1) inhibitor therapy can be a viable treatment option for disseminated Mycobacterium avium infection in patients with human immunodeficiency virus who are refractory to standard treatments.
• PD-1 inhibition may restore T-cell function and enhance pathogen-specific immune responses, leading to infection clearance.